Podcasts about Cart

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Episodio exclusivo para suscriptores de Se Habla Español en Apple Podcasts, Spotify, iVoox y Patreon: Spotify: https://open.spotify.com/show/2E2vhVqLNtiO2TyOjfK987 Patreon: https://www.patreon.com/sehablaespanol Buy me a coffee: https://www.buymeacoffee.com/sehablaespanol/w/6450 Donaciones: https://paypal.me/sehablaespanol Contacto: sehablaespanolpodcast@gmail.com Facebook: www.facebook.com/sehablaespanolpodcast Twitter: @espanolpodcast Hola, ¿cómo va todo? Aquí en Luxemburgo ya estamos viviendo el espíritu de la Navidad, porque este fin de semana han abierto los mercadillos navideños, concretamente el pasado viernes 21 de noviembre. Como en este país no se celebra la fiesta de los Reyes Magos, la Navidad termina el 1 de enero. Ya sabes que en España termina el día 6, aunque los estudiantes suelen tener libre incluso el 7 de enero. Y estas fechas son muy especiales para las familias que tienen a alguien enfermo, sobre todo si es un niño o un adolescente. A todas ellas, un abrazo muy fuerte desde aquí, y también una buena noticia que compartir. Porque hoy vamos a hablar de un tema muy importante: la lucha contra el cáncer y un nuevo tratamiento que está funcionando en España. Pero antes vamos a explicar algunas diferencias entre la sanidad pública y la sanidad privada en mi país. En España, la sanidad pública está financiada por los impuestos y las cotizaciones sociales. Esto significa que, si trabajas y cotizas, tienes acceso gratuito a médicos, hospitales y urgencias. Solo hay que pagar una parte de los medicamentos, lo que se llama copago. Por ejemplo, una persona con ingresos bajos puede pagar unos 8 euros por un medicamento que cuesta mucho más. Por otro lado, la sanidad privada funciona con seguros médicos. Las personas pagan una póliza mensual para tener acceso más rápido a especialistas, elegir médico o recibir servicios extra como atención dental o revisiones oftalmológicas, de la vista. Los precios varían: un joven puede pagar unos 20 o 30 euros al mes, mientras que una persona mayor puede pagar más de 100 euros mensuales. Muchas personas en España combinan ambos sistemas: usan la sanidad pública para lo esencial y contratan un seguro privado para evitar listas de espera o tener más comodidad. Con esta información como contexto, vamos a escuchar una noticia que nos habla de un avance médico realizado en un hospital público. Y es que el Hospital de La Paz, en Madrid, ha conseguido curar a varios niños con leucemia gracias a una terapia experimental. A lo largo del episodio, vamos a aprender vocabulario relacionado con este tema. Pero lo primero es escuchar la noticia, que pertenece una vez más a Radio Nacional de España. Presta mucha atención. “La sanidad pública, concretamente el Hospital de la Paz en Madrid, ha logrado salvar a 8 niños y adolescentes con cáncer, con una forma agresiva de leucemia, que ya no tenían ninguna opción de curarse. Lo han logrado gracias a una terapia experimental con células y ahora hacen vida normal. Nos lo ha contado Lucía, tiene 15 años y gracias a este tratamiento, también muchos planes de futuro. Y nos ha contado varias cosas. La primera es que quiere estudiar Biología, la segunda es que en el colegio la están arropando mucho y la tercera y la más importante es que está curada. Ahora me siento genial. Normalmente tengo recaídas al año y mucho, pero no he tenido nada y estoy muy contenta porque parece que ahora sí, pues estoy curada. Tras 15 años de lucha contra la leucemia y cuatro recaídas, Lucía ha comenzado a hacer vida normal. El tratamiento conocido como CAR-T en tándem ha sido aplicado en 10 pacientes que ya habían pasado por quimioterapia y por trasplante para frenar el avance de la enfermedad. 8 de esos menores ya están curados. El gran problema de la leucemia son las recaídas y es que las células tumorosas, tras la primera medicación, son capaces de ocultarse en algunas moléculas para pasar desapercibidas y posteriormente volver a atacar. Lo que hace este tratamiento es fijar dos moléculas a la vez y dejar al cáncer sin escondite posible. El resultado, lo decíamos, 8 niños curados y una nueva esperanza para poder derrotar definitivamente la enfermedad.” La verdad es que da gusto escuchar noticias positivas relacionadas con el cáncer, porque es una enfermedad que termina con la vida de miles de personas cada año, y los avances médicos suelen tardar mucho tiempo en llegar. Pero bueno, de vez en cuando aparecen nuevos tratamientos que funcionan, como el que nos han contado en la noticia. Con respecto al vocabulario, no he encontrado mucho que explicar, pero vamos a reforzar algunos conocimientos para que estén todavía más claros. Terapia experimental: Tratamiento médico nuevo que aún está en fase de prueba y no se ha aprobado oficialmente para su uso general. Ejemplos: Los médicos aplicaron una terapia experimental para tratar el cáncer que no respondía a otros tratamientos. Aunque es una terapia experimental, ha mostrado resultados muy prometedores en algunos pacientes. Hacer vida normal: Volver a la rutina diaria habitual después de una enfermedad o situación difícil. Ejemplos: Después de la operación, pudo hacer vida normal y volver al trabajo. Lucía ha empezado a hacer vida normal tras superar la leucemia. Arropar: En sentido figurado, significa proteger, apoyar o dar cariño a alguien, especialmente en momentos difíciles. Ejemplos: Su familia lo arropó durante todo el tratamiento. En el colegio, los profesores y compañeros la están arropando mucho. Recaída: Cuando una persona vuelve a enfermar después de haber mejorado o superado una enfermedad. Ejemplos: Tras varios meses sin síntomas, tuvo una recaída y volvió al hospital. Las recaídas son comunes en enfermedades como la leucemia. Pasar desapercibida: No ser notado o detectado; en medicina, se refiere a células o síntomas que no se identifican fácilmente. Ejemplos: Las células cancerosas pueden pasar desapercibidas tras el primer tratamiento. Su talento no pasó desapercibido en el concurso de canto. Fijar: En medicina, significa unir o dirigir algo hacia un objetivo específico; también puede significar establecer o asegurar algo. Ejemplos: El tratamiento fija dos moléculas para atacar el cáncer sin dejarle escondite. Han fijado la fecha de la operación para el próximo lunes. Muy bien. Como te decía, el resto del vocabulario es bastante sencillo, y supongo que lo conoces perfectamente. Así que, escuchamos la noticia por segunda vez. “La sanidad pública, concretamente el Hospital de la Paz en Madrid, ha logrado salvar a 8 niños y adolescentes con cáncer, con una forma agresiva de leucemia, que ya no tenían ninguna opción de curarse. Lo han logrado gracias a una terapia experimental con células y ahora hacen vida normal. Nos lo ha contado Lucía, tiene 15 años y gracias a este tratamiento, también muchos planes de futuro. Y nos ha contado varias cosas. La primera es que quiere estudiar Biología, la segunda es que en el colegio la están arropando mucho y la tercera y la más importante es que está curada. Ahora me siento genial. Normalmente tengo recaídas al año y mucho, pero no he tenido nada y estoy muy contenta porque parece que ahora sí, pues estoy curada. Tras 15 años de lucha contra la leucemia y cuatro recaídas, Lucía ha comenzado a hacer vida normal. El tratamiento conocido como CAR-T en tándem ha sido aplicado en 10 pacientes que ya habían pasado por quimioterapia y por trasplante para frenar el avance de la enfermedad. 8 de esos menores ya están curados. El gran problema de la leucemia son las recaídas y es que las células tumorosas, tras la primera medicación, son capaces de ocultarse en algunas moléculas para pasar desapercibidas y posteriormente volver a atacar. Lo que hace este tratamiento es fijar dos moléculas a la vez y dejar al cáncer sin escondite posible. El resultado, lo decíamos, 8 niños curados y una nueva esperanza para poder derrotar definitivamente la enfermedad.” Sé que lo tienes todo muy claro, pero ya sabes que me gusta ofrecerte la noticia cambiando algunas palabras para que puedas ampliar tu vocabulario. Y es lo que voy a hacer ahora mismo. La información se refiere al sistema médico público, en concreto el Hospital de La Paz en Madrid, porque ha conseguido devolverle la salud a ocho menores —niños y adolescentes— que padecían cáncer, una variante severa de leucemia, y que ya no contaban con ninguna alternativa de recuperación. Este logro ha sido posible gracias a un procedimiento innovador con células, y ahora estos jóvenes han vuelto a tener una rutina habitual. Una de ellas, Lucía, de 15 años, ha compartido su experiencia con Radio Nacional de España. Y gracias a este método terapéutico, tiene muchos proyectos para el futuro. En concreto, Lucía ha revelado tres cosas importantes: la primera, que desea estudiar Biología; la segunda, que en el colegio la están apoyando emocionalmente mucho; y la tercera, y más relevante, que está libre de la enfermedad. Dice que se encuentra fenomenal. Antes solía tener reapariciones de la enfermedad cada año, y bastante fuertes, pero esta vez no ha tenido ninguna, y está muy feliz porque parece que, por fin, está curada. Después de 15 años de batalla contra la leucemia y cuatro recaídas, Lucía ha comenzado a retomar su vida cotidiana. El tratamiento, conocido como CAR-T en combinación, se ha aplicado a diez pacientes que ya habían pasado por quimioterapia y por trasplantes para intentar detener el avance de la dolencia. Ocho de ellos ya están libres de cáncer. El gran desafío de la leucemia son las reapariciones, ya que las células malignas, tras el primer tratamiento, pueden camuflarse en ciertas moléculas para no ser detectadas y luego volver a atacar. Lo que hace este tratamiento es dirigirse simultáneamente a dos moléculas y dejar al cáncer sin posibilidad de esconderse. El resultado, como decíamos, ocho menores recuperados y una nueva ilusión para vencer definitivamente esta enfermedad. Por cierto, me gusta mucho el verbo “camuflarse”, que es como esconderse, pero utilizando alguna estrategia especial. Por ejemplo, podemos camuflarse con un disfraz para que nadie sepa quiénes somos. Venga, vamos a escuchar la noticia por última vez y te cuento más detalles sobre el impacto del cáncer en España. “La sanidad pública, concretamente el Hospital de la Paz en Madrid, ha logrado salvar a 8 niños y adolescentes con cáncer, con una forma agresiva de leucemia, que ya no tenían ninguna opción de curarse. Lo han logrado gracias a una terapia experimental con células y ahora hacen vida normal. Nos lo ha contado Lucía, tiene 15 años y gracias a este tratamiento, también muchos planes de futuro. Y nos ha contado varias cosas. La primera es que quiere estudiar Biología, la segunda es que en el colegio la están arropando mucho y la tercera y la más importante es que está curada. Ahora me siento genial. Normalmente tengo recaídas al año y mucho, pero no he tenido nada y estoy muy contenta porque parece que ahora sí, pues estoy curada. Tras 15 años de lucha contra la leucemia y cuatro recaídas, Lucía ha comenzado a hacer vida normal. El tratamiento conocido como CAR-T en tándem ha sido aplicado en 10 pacientes que ya habían pasado por quimioterapia y por trasplante para frenar el avance de la enfermedad. 8 de esos menores ya están curados. El gran problema de la leucemia son las recaídas y es que las células tumorosas, tras la primera medicación, son capaces de ocultarse en algunas moléculas para pasar desapercibidas y posteriormente volver a atacar. Lo que hace este tratamiento es fijar dos moléculas a la vez y dejar al cáncer sin escondite posible. El resultado, lo decíamos, 8 niños curados y una nueva esperanza para poder derrotar definitivamente la enfermedad.” Como te decía, para concluir vamos a repasar las estadísticas más recientes sobre el cáncer infantil en España. En 2024 se registraron alrededor de 1.500 casos nuevos en niños menores de 14 años. Pero lo realmente alentador es el avance en las tasas de supervivencia. Según los últimos informes, la tasa de supervivencia a cinco años tras el diagnóstico se sitúa en un impresionante 83,9 % para menores de 0 a 14 años. Esta cifra refleja una mejora constante en comparación con décadas atrás; en los años ochenta y noventa la supervivencia estaba muy por debajo, entre el 60 % y el 70 %. Estos datos ponen en evidencia que la investigación médica y los avances terapéuticos han conseguido que hoy más del 80 % de los niños con cáncer logren superarlo. Se evidencia también que cuanto más tiempo pasa tras el diagnóstico —especialmente superados los cinco años— menor es el riesgo de recaída, gracias a programas de seguimiento sólido que permiten detectar y tratar a tiempo posibles complicaciones. Este progreso va de la mano de innovaciones como la terapia CAR‑T, de la que hemos hablado hoy, y de los múltiples esfuerzos en medicina personalizada y oncología pediátrica. El mensaje es claro: aunque cada año se diagnostican nuevos casos, las posibilidades de curación siguen mejorando, ofreciendo un horizonte mucho más esperanzador para niños y adolescentes afectados. Y ahora, como siempre, repasamos las palabras y expresiones que hemos explicado hoy. Terapia experimental: Tratamiento médico nuevo que aún está en fase de prueba y no se ha aprobado oficialmente para su uso general. Hacer vida normal: Volver a la rutina diaria habitual después de una enfermedad o situación difícil. Arropar: En sentido figurado, significa proteger, apoyar o dar cariño a alguien, especialmente en momentos difíciles. Recaída: Cuando una persona vuelve a enfermar después de haber mejorado o superado una enfermedad. Pasar desapercibida: No ser notado o detectado; en medicina, se refiere a células o síntomas que no se identifican fácilmente. Fijar: En medicina, significa unir o dirigir algo hacia un objetivo específico; también puede significar establecer o asegurar algo. Pues esto ha sido todo por hoy. Espero que la noticia te haya alegrado tanto como a mí, porque muchas veces sólo escuchamos malas noticias en los medios de comunicación. Ojalá encuentre más informaciones de este tipo en el futuro para poder hablar de ellas aquí. Mil gracias de nuevo por tu apoyo y hasta la próxima semana. Adiós. Escucha este episodio completo y accede a todo el contenido exclusivo de Se Habla Español. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/171214

Fast food restaurants like Wendy's are experiencing a slowdown in business The fast-food restaurant Wendy's is planning on closing hundreds of locations throughout next year because they continue to see a slowdown in spending from their customers. They said most of their low-income consumers are cutting spending and making fewer trips with smaller purchases at the restaurants. Wendy's increased prices after the pandemic at a higher rate than grocery stores and now other fast-food restaurants have begun to add value menus to keep customers coming back, but Wendy's has held firm and not created any values for their customers. Because of this they have seen their net income decline to $44.3 million from a year ago when it was $50.2 million. Over the past year the stock has declined from around $18 a share down to under $9 a share, which is a decline of 53%. With the reduction in the stock price, the dividend yield is now 6.5% and the company trades at 10 times earnings on a forward basis. This company may be worth looking into as an investment as within in the next 6 to 12 months we could see lower end consumers stabilize.   The affordability index for people buying a home is the worst in 50 years People may be excited about buying a home because mortgage rates are around the lowest they've been in over a year, but the affordability of a home is still far out of reach for many. The reason for this, and we have talked about this for the last few years, is that the increase in the price of homes has far outpaced the increase in people's income. The 50-year average for a price-to-income ratio is around four times, and it reached a low in 1999 of around 3.6 times. But with the rapid increase of homes over the last few years, the price to income ratio has climbed to slightly over five times. Also not helping are the increases in home insurance costs and property taxes. Back in the summer of 2019, when looking at households earning $75,000, nearly 50% of those people could afford to buy a home. Today, when looking at those same households earning $75,000, only 21% would be able to afford a home. Back in 2012, the home affordability index was over 200, but it has now been cut in half to just about 100 with no signs of improving any time soon. I believe it will probably take 3 to 5 years to correct itself. If you look back in history, the affordability index does not change overnight. What will happen is probably incomes will increase slightly over the next 3 to 5 years and maybe the price of homes will either stay the same or decline slightly, which would increase the affordability index. What this means for people buying a home today is you should not have any aspirations of a rapid increase in the value of your home. What caused the problem was during the pandemic mortgage rates dropped to lows not seen in 50 years and that pushed up demand and the prices for homes climbed at a rapid rate. I believe this scenario is extremely unlikely to play out again! The brokerage firm Robinhood looks more like a gambling platform than a brokerage firm Robinhood initially went public at $38 a share in 2023 and the stock then fell to under $10 a share. It has recovered nicely since then as it's now trading around $110 a share. What has caused this shift and the huge increase in the stock price? One big reason is that the company has really allowed major speculation for their investors. Starting off with crypto, they have allowed people to buy coins like BONK, Dogwifhat and Pudgy Penguins. Just when you think there's no way they could come up with anything more speculative, surprise; they have come up with an investment known as prediction markets and event trading. Somehow the regulators have let this slide or maybe since government agencies don't move that quickly, it just has not been addressed yet. It appears for investors on their app that you can predict what the outcome will be of a football game, politics, contracts over economics, even if aliens will exist on earth this year. Chief Brokerage Officer, Steve Quirk, says this is the fastest growing business we have ever had. Robinhood stock trades over 50 times projected earnings and is looking for about $4.5 billion in revenue, which is an increase of 53% over last year. The growth appears to be there for the company, but there is so much speculation and insane crazy things there is no doubt in my mind that in the future many people will lose more money than they ever thought was possible by speculating on crazy things rather than investing into good quality businesses. A fallout in those risky "investments" could hurt Robinhood's reputation, which I believe would be bad for long term growth.    Financial Planning: The Real Cost of Employer Coverage vs. Medicare When reaching age 65, sometimes there is the option to join Medicare or stay with an employer health insurance plan.  This is most common when a spouse retires after age 65 and they have the ability to join their spouse's work plan. When comparing the cost of coverage, there is a key difference in how each affects your tax bill. Premiums paid through payroll for employer-sponsored health insurance are pre-tax, meaning you avoid federal, state, and payroll taxes such as the 6.2% Social Security, 1.45% Medicare, and 1.2% CA SDI tax in California.  This is different from a 401(k) for example where contributions are only pre-tax from federal and state taxes. For someone in the 22% tax bracket, a $500 premium would be around $300 after the tax savings. Medicare premiums on the other hand are paid with after-tax dollars and are only tax-deductible for people who itemize and have total medical expenses exceeding 7.5% of AGI, which means very few retirees actually receive any tax benefit. Additionally, Medicare Part B and D premiums may be elevated due to higher levels of income because of IRMAA. Employer health insurance can vary in coverage and cost so at times Medicare may be a more comprehensive and cost-effective option, but it is necessary to compare the after-tax costs to be sure.   Companies Discussed: Cisco Systems, Inc. (CSCO), The Walt Disney Company (DIS), Spectrum Brands Holdings, Inc. (SPB), Maplebear Inc. (CART)

Prosecutors allege that during a video-conference session with her lawyers at MDC Brooklyn, Maxwell used a large cart loaded with legal documents to block the door of a dedicated conference room, effectively preventing prison staff from entering. The filing states she was permitted to bring the cart into the video‐teleconference (VTC) room for meetings, but then “used that cart to barricade the door to the room” when staff attempted to gain access.In response, Maxwell's legal team denied the barricade claim, arguing the government was “gratuitously casting” her in a negative light to justify stricter limits on her legal material access. Following the incident, prison authorities removed and banned the use of the cart during her meetings, directing that she instead carry her documents by hand and make multiple trips if needed.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Happy Thursday you pop culture junkies!   This week's pod takes a look at the hilarious social media reactions to the rainstorm in Los Angeles. Angelenos really do lose it the moment a single raindrop hits the ground, and the memes did not disappoint. We also dive into the newest gourmet food sensation in New York, Meadow Lane, opened by a social media influencer and quickly becoming the Erewhon of the East Coast.   Plus, we get into the absolute travesty of Apple's latest accessory, the iPhone Pocket, and why the internet is collectively cringing. There are also some wonderfully awkward TikTok trends making the rounds that we can't ignore. And as always, we wrap with what to watch this week — from new releases to comfort binges you'll be obsessed with.   https://popculturemondays.com/2025/11/17/its-raining/

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.Featured ArticlesIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)A bispecific nanobody for the treatment of von Willebrand disease type 1

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, which led to a significant drop in their stock value. This scenario underscores the complexities of navigating clinical trial outcomes while pursuing breakthroughs in treating challenging diseases like sickle cell.Arrowhead Pharmaceuticals has marked a significant milestone with the FDA's approval of Plozasiran. This achievement not only marks Arrowhead's entry into the commercial sector but also highlights the competitive dynamics within biotech, as companies like Ionis Pharmaceuticals vie for market dominance with innovative therapies. Further strengthening its position, Arrowhead also received FDA approval for Redemplo, a siRNA-based therapeutic for rare genetic metabolic disorders. Despite facing volatility due to safety concerns in its partnership with Sarepta Therapeutics, this approval underscores RNA interference therapies' potential in precision medicine.In corporate strategy news, Alkermes is making moves to acquire Avadel Pharmaceuticals, offering up to $2.37 billion and overshadowing a competing bid from Lundbeck. Such acquisitions are part of a broader trend of consolidation in the industry aimed at expanding portfolios and market reach. Avadel's decision to accept Alkermes' revised offer over Lundbeck's bid highlights ongoing consolidation trends as companies expand their portfolios in competitive markets like narcolepsy drugs.On the investment front, Celltrion has committed $478 million to upgrade a U.S. manufacturing facility acquired from Eli Lilly. This expansion is crucial for increasing manufacturing capabilities within the biosimilars sector, where demand for cost-effective therapeutics is on the rise. Additionally, Celltrion's exploration beyond biosimilars with a potential $350 million deal involving Trioar's antibody platform demonstrates ambition to diversify its portfolio towards innovative biologics.Teva Pharmaceuticals is fostering innovation by inviting startups to tackle key challenges within biopharma through a global platform. This initiative reflects a growing trend toward open innovation and collaboration, seeking novel solutions to complex issues across research and development and manufacturing efficiencies.In regulatory news, the controversial $7.4 billion settlement plan involving the Sackler family and Purdue Pharma has received approval from a bankruptcy judge. This paves the way for Purdue's transformation into Knoa Pharma and highlights ongoing legal and ethical reckonings related to opioid liabilities within the industry.Cytokinetics remains committed to its independent path as it awaits FDA approval for its cardiovascular drug Aficamtem. The company's determination to commercialize without big pharma support reflects a trend where smaller biotech firms strive for autonomy while bringing first-in-class drugs to market.On an infectious disease front, Merck has demonstrated significant progress with its HIV treatment Islatravir in Phase 3 trials. This places Islatravir as a potential competitor against Gilead's Biktarvy, showcasing ongoing innovation within antiviral drug development.Additionally, Dexcom has gained clearance for its type 2 diabetes software integrating continuous glucose monitoring technology. This advancement exemplifies how digital health technologies are transforming chronic disease management bySupport the show

Action1, Cart.com, and Tellihealth, all based in Houston, secured spots on the Deloitte Technology Fast 500 list, which ranks North America's fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies by three-year revenue growth. Action1 provides cloud-based endpoint security and patch management, Cart.com offers an e-commerce platform for online sales and logistics, and Tellihealth delivers remote patient monitoring solutions. Their inclusion highlights Houston's increasing presence in the national technology sector.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

This is a free preview of a paid episode. To hear more, visit meetthemess.substack.comMove over, Meet the Press—it's time to MEET THE MESS!This week on the podcast, Jen and Karyn are back! The House voted to release the Epstein files, but will it actually happen? Meanwhile, Trump delivers a completely bananas speech to McDonald's franchise owners and tells a female reporter, “Quiet, piggy.”Also on deck: a behavioral scientist breaks down what it means when someone does (or doesn't) return their cart. Plus, Kim Kardashian fails the bar exam, the FDA removes the black box warning from menopause hormone therapy, and a flamingo escapes a British zoo and decides to retire on a beach in the south of France. And finally, do you have a preferred font?On Meet the Mess, bestselling authors Jen Lancaster & Karyn Bosnak dive into the messiest news stories and hottest topics of the week to give a fresh and entertaining take on current events and life in general. An extended video version with the “Hot Mess of the Week” is available to paid Substack subscribers. Visit meetthemess.substack.com for more.Meet the Merch:• https://www.etsy.com/shop/MeetTheMessConnect with us on Instagram:• https://www.instagram.com/meetthemesspod• https://www.instagram.com/jennsylvania• https://www.instagram.com/karynbosnakConnect with us on TikTok:• https://www.tiktok.com/@meetthemess• https://www.tiktok.com/@karynbosnak

Programa de Radio No.370, Podcast No.519Transmitido el 19 de noviembre de 2025 por Radio y TV. Querétaro 100.3 FMEn  esta ocasión Pablo entrevisto al músico y compositor Canadiense Jazz Paladin y nos platica sobre sus más recientes trabajos musicalizando el juego de mesa Uprising y más trabajos en los que ha colaborado además de arreglos de música de videojuegos; no se pierdan este programa con una variedad de música muy interesante hecha por este compositor.

If you're a leader in game dev who feels stuck, there is a path forward that levels up your leadership and accelerates your team, game, and career. Sign up here to learn more: https://forms.gle/nqRTUvgFrtdYuCbr6 Are you leading a team that has plenty of people but can't seem to get moving? You care deeply about your team and your game, but projects crawl and decisions drag in the. It's almost never just a talent problem. Instead, it's three quiet leadership mistakes that choke momentum. In this episode, you'll learn what those three mistakes are, how they're showing up in your studio, and what you can do instead so you can move faster and see real progress on your game. We break down the mistakes one by one with simple shifts you can start immediately. What You'll Learn: The Velocity Trap: Why any speed you have is "pretend" if your team doesn't share a clear North Star (Vision). The Cart in the Mud: The four specific foundational elements you must have in place to earn the right to scale , and what to do when you realize you've scaled too fast. The Crunch Lie: Why overwork and extended crunch quickly make you slower than if you never crunched at all, and how to operate at a sustainable pace. A Simple Reality Check: How to rate your studio's Vision, Scale, and Workload (1-5) to identify your biggest blocker and immediately focus your leadership energy. GameDeveloper.com Article: https://www.gamedeveloper.com/production/addressing-crunch-the-games-industry-s-worst-practice-2 Connect with us:

Every successful surgery starts with a perfectly assembled case cart. But what happens when the next cart rolling into the OR is missing a critical supply or instrument? This week, we're joined by Courtney Kleeb, Senior Director of Perioperative Surgical Solutions at HealthTrust Performance Group, for a deep dive into what really drives case cart success. From preference card cleanup to fixing inefficient pick paths that send your team zigzagging, Courtney breaks down the real-world strategies that turn incomplete carts into streamlined workflows. Whether you're dealing with multiple departments all touching the same cart or just tired of chasing down missing supplies between cases, this conversation has the practical solutions you need to unite your OR, SPD, and Supply Chain around one goal—delivering excellent patient care! Season 30 of Beyond Clean releases under the 1 Episode = 1 CE delivery model. After finishing this interview, earn your 1 CE credit immediately by passing the short quiz linked here: https://www.flexiquiz.com/SC/N/episode30-07 Visit our CE Credit Hub at https://www.beyondcleanmedia.com/ce-credit-hub to access this quiz and over 350 other free CE credits. #BeyondClean #SterileProcessing #Podcast #Season30 #TrayCommand #CaseCarts #Accuracy #Surgery #SurgicalSupplies #Instruments

In a conversation with CancerNetwork®, Michael Barish, PhD, spoke about an investigational CAR T-cell therapy that he and colleagues are developing as a treatment for patients with glioblastoma. He and his team designed the agent to harness chlorotoxin, an amino acid peptide toxin component of scorpion venom, as a vehicle for intratumoral delivery of therapy for this patient population. Barish, a chair in the Department of Neurosciences/Developmental & Stem Cell Biology at City of Hope, discussed the background and mechanisms surrounding this novel compound, which he and colleagues evaluated as part of a phase 1 trial (NCT04214392). Early findings published in Cell Reports Medicine showed that among 4 patients with recurrent glioblastoma, 3 (75%) achieved a best response of stable disease. Additionally, the chlorotoxin-directed cellular therapy was found to be well-tolerated with no dose-limiting toxicities. Although responses were not as strong as Barish and colleagues had hoped, he described how the study nevertheless demonstrated the safety and feasibility of this CAR T-cell therapy formulation.  After establishing the safety of the novel agent in patients with recurrent glioblastoma, Barish highlighted how next steps for research included engineering different versions of the chlorotoxin and modifying the T cells that express the chimeric receptor. He stated these reconfigurations may help yield additional power and efficacy of the cellular therapy in future studies. Overall, Barish noted how the potential therapeutic application of the neurotoxin represented a “proof of principle.” “[V]enoms of many invertebrates are, in fact, very powerful biologically. In a sense, evolution has honed them to be relatively specific. Neurobiology is very much driven by the specificity of different toxins for different ion channels,” Barish stated. “This idea—that one could use biological products efficiently this way for something as heterogeneous as glioblastoma—might be an example of how it could be more efficacious for other solid tumors as well.” Reference Barish ME, Aftabizadeh M, Hibbard J, et al. Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: interim clinical experience demonstrating feasibility and safety. Cell Rep Med. 2025;6(8):102302. doi:10.1016/j.xcrm.2025.102302.

Bryan Nooner, Owner & CEO of Midwest Innovations, joins HouseSmarts Radio for Lou's Cool Products Show to share the Rhino Cart, a lightweight, but heavy-duty moving cart that can move up to 2,000lbs! Get yours at rhinocart.com.

C'est la libre-antenne du dimanche midi ! Attablez-vous et venez débattre avec la joyeuse bande de Stephen Brun tous les dimanches entre 13h00 et 15h00. Durant deux heures, les auditeurs sont au cœur de l'émission pour échanger avec Stephen Brun, Alexandre Biggerstaff, Maxime Pauty, Erwan Abautret et tous leurs invités.

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.

Subscribe to DTC Newsletter - ⁠https://dtcnews.link/signup⁠Welcome to the episode: we've got Jordan Gordon back on the mic — the guy leading email, retention and CRO at Pilot House, with 25 years in ecommerce under his belt.Role‑Based Hook (for DTC growth/marketing audience):For DTC founders & growth marketers scaling from $5M–100M in revenue, this is your CRO check‑list for Q4.Here's what we dig into:Why your headline conversion rate is a shaky metric — and why “direct conversion” gives you better signal.The one page type (your top product page) you can fix in time for Black Friday to move the needle.How to push “bundling and recommendations” tools to unlock +8–30% lift in AOV with zero extra ad spend.The eight choke‑points across homepage → category → PDP → cart/checkout you must optimize right now.Real copy & button tips: How a tiny phrase (“Feel organic again”) can flip the homepage from meh to go‑time.Who this is for: DTC brand leads, ecommerce CRO/optimization folks, retention & growth marketers who already run advertising and now need to tighten the funnel.What to steal:Run quick benchmark: Are you hitting 5‑7% Add‑to‑Cart, ~2% conversion, ~1.25% direct conversion in Shopify?Pick your top 3‑5 PDPs and make them ultra‑fast (under 3s load) using a tool/tech stack like Niche.Install a bundling/recommendation engine (like Rebuy) across the site and measure +8% lift in AOV by pushing “people like you bought this + add it” flows.Timestamps00:00 Highest Leverage CRO Insights for Q402:10 Benchmarking Add-to-Cart and Conversion Rates04:45 Why Direct Conversion Is a Better Signal07:00 Speeding Up PDPs with Niche for Instant Wins10:05 Boosting AOV with Rebuy Bundling13:00 The 8 Critical Website Choke Points15:45 Optimizing Copy Around Key Conversion Areas18:20 Homepage Strategy for High-Volume Traffic21:40 What Big Brands Get Right on Their Homepages24:30 Final Q4 CRO Checklist and Fast WinsHashtags#dtcpodcast #q4ecommerce #cro #conversionrateoptimization #ecommercetips #shopifygrowth #blackfridayprep #aov #d2cbrands #onlinescaling Subscribe to DTC Newsletter - https://dtcnews.link/signupAdvertise on DTC - https://dtcnews.link/advertiseWork with Pilothouse - https://www.pilothouse.co/?utm_source=AKNF559Follow us on Instagram & Twitter - @dtcnewsletterWatch this interview on YouTube - https://dtcnews.link/video

Welcome to another electrifying episode of the Lighting Controls Podcast! This time, we're joined by industry veteran Dave Werry, who brings over a decade of hands-on experience in lighting systems, engineering, and field service. 

Send us a textUnderstanding your Amazon customer journey is crucial for sales growth. Learn how to analyze awareness, consideration, and purchase stages to optimize your strategies with the help of My Amazon Guy's expert insights. Discover the steps you can take to fine-tune your advertising and customer targeting for maximum success.Get your hands on the Ultimate Q4 Playbook for Amazon sellers and crush this holiday season! https://bit.ly/46Wqkm3Book a strategy call to dive deeper into your customer journey analytics and unlock real growth for your brand: https://bit.ly/4jMZtxu#AmazonSales #EcommerceGrowth #CustomerJourney #AmazonAdvertising #brandgrowth Watch these videos on YouTube:Use Brand Analytics to Increase Sales https://www.youtube.com/watch?v=HnUKZXZ9uEk&list=PLDkvNlz8yl_b9RMGmU9XeqkI9D7QDOAI8&index=4Simplify Amazon Listing Compliance https://www.youtube.com/watch?v=ArGPygUCFpk&list=PLDkvNlz8yl_b9RMGmU9XeqkI9D7QDOAI8&index=11-----------------------------------------------Plan your best sales season yet with our 2025 Ecommerce Holiday Playbook: https://bit.ly/4hbygovStop wasting ad spend,download our PPC guide and run campaigns that actually convert: https://bit.ly/4lF0OYXFix what's burying your listings, download the SEO toolkit sellers rely on for rankings: https://bit.ly/3JyMDGoDon't wait for chaos, grab the Amazon Crisis Kit before your traffic or rankings take a hit: https://bit.ly/4maWHn0Timestamps00:00 - Amazon Data & Customer Journey01:10 - Understanding the Amazon Customer Journey Funnel02:20 - Analyzing the Awareness Stage: Key Metrics03:40 - Identifying High Potential Customers in Consideration05:00 - The Importance of Add-to-Cart and Wishlist Data06:15 - How to Optimize Your Amazon Sales Funnel for Better Conversion07:30 - Comparing January vs. March: Key Data Shifts08:45 - Improving New-to-Brand Purchases with Targeted Strategies10:00 - Retargeting Strategies for Repeat Customers on Amazon11:15 - How to Leverage Customer Journey Data to Grow Your Brand----------------------------------------------Follow us:LinkedIn: https://www.linkedin.com/company/28605816/Instagram: https://www.instagram.com/stevenpopemag/Pinterest: https://www.pinterest.com/myamazonguys/Twitter: https://twitter.com/myamazonguySubscribe to the My Amazon Guy podcast: https://podcast.myamazonguy.comApple Podcast: https://podcasts.apple.com/us/podcast/my-amazon-guy/id1501974229Spotify: https://open.spotify.com/show/4A5ASHGGfr6s4wWNQIqyVwSupport the show

In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic leukemia treatment. Dr. Semple explored how mitochondrial DNA could act as a first hit in lung injury, while Dr. Al-Sawaf revealed that patient fitness may not significantly impact the efficacy of targeted CLL treatments. Both studies challenge existing medical assumptions and suggest new approaches to understanding disease mechanisms and treatment responses.Featured ArticlesThe impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLMitochondrial DNA via recipient TLR9 acts as a potent first-hit in murine transfusion-related acute lung injury (TRALI)

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Do the 2001 Patriots compare to the 2025 Patriots in significant ways? // Former Patriots' QB Brian Hoyer joins, says Pats are the real deal // Comparing Maye to Brady //

Editor-in-Chief of Molecular Therapy, Dr. Joseph Glorioso, is joined by Rachael Nimmo, PhD, former director of the Cell Technology Group at Oxford Biomedica, and Kyriacos Mitrophanous, PhD, Chief Innovation Officer at Oxford Biomedica, to discuss an article recently published in Molecular Therapy by Nimmo and colleagues titled “Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.” Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

HOUR 4: ARE THE CART CORRALS AFFIXED OR NOT AFFIXED?! That is the question. full 2118 Mon, 10 Nov 2025 23:00:00 +0000 BYpLLrNBGkJzXjHRjldrmzcuuqbqEygf news The Dana & Parks Podcast news HOUR 4: ARE THE CART CORRALS AFFIXED OR NOT AFFIXED?! That is the question. You wanted it... Now here it is! Listen to each hour of the Dana & Parks Show whenever and wherever you want! © 2025 Audacy, Inc. News False https://player.am

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into: • An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. • Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias. • Unique side effects associated with each TKI and strategies for dose optimization. • The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Memory chip stocks like SanDisk (SNDK), Seagate (STX) and Western Digital (WDC) gathered more bullish traction from firms like Loop Capital and Barclays. Diane King Hall explains where the Street is seeing more upside for these companies and the role A.I. plays in their theses. Healthcare stocks dipped after President Trump made comments against health insurers on Truth Social. Diane later turns to Instacart's parent company, Maplebear (CART), which delivered a double-win in earnings through a beat and share buyback announcement.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Join Dr. Adam Brockman as he reveals the hidden power of your grocery cart in shaping your health and longevity. Discover the quiet revolution in functional foods that not only satisfy your cravings but also enhance your well-being. From the clean label movement to personalized nutrition, learn how to make informed choices that can add years to your life. It's time to take control of your health—one shopping trip at a time!Special Guest: Daniel Scharff, Founder of Startup CPG

00:00: ☀️ Bom dia Tech!01:12: ⚡ OpenAI pede apoio do governo dos EUA para acelerar construção de data centers de IA02:35:

Na Conversa com Zé Márcio, o economista-chefe da Genial Investimentos, José Márcio Camargo, recebe José Roberto Mendonça de Barros, da MB Associados, para uma análise afiada dos impasses econômicos que desafiam Brasil e mundo. A escalada tarifária nos EUA, o risco de bolha nas gigantes de tecnologia e os dilemas do FED se cruzam com a queda da inflação brasileira, puxada pela supersafra, e o alerta fiscal em ano pré-eleitoral. Um episódio para quem quer entender o que está por trás dos números.DIRETO AO PONTO0:00 — Cartão Black Genial Investimentos0:44 — Apresentação e boas-vindas1:03 — Revisão da política comercial de Trump e do cenário internacional2:49 — Reação do mercado e risco de reajuste dos ativos (Magníficas Sete)4:11 — O impacto do aumento de tarifas na inflação americana6:02 — Contradições na economia dos EUA e o dilema do Fed8:15 — Risco de bolha financeira e ciclos tecnológicos10:22 — Inflação e crescimento: o efeito contraintuitivo das tarifas12:26 — O impulso do setor de tecnologia e o repasse tardio da inflação13:45 — Inflação estrutural e a dificuldade do Banco Central americano15:51 — Sustentabilidade dos valuations do setor de tecnologia (Asset Heavy Status)17:41 — Consequências da desvalorização do dólar para o Brasil19:43 — Fatores de queda da inflação brasileira (externos e internos)21:41 — O efeito da supersafra agrícola na desinflação24:40 — Decisão do Copom e o debate: queda de juros em janeiro ou março?26:42 — Aperto financeiro nas empresas e a crise de RJs no agronegócio28:17 — A grande preocupação com a política fiscal expansionista31:31 — Programas fiscais para 2024 e antecipação da sucessão presidencial33:36 — Cenário pós-eleitoral: dívida elevada e o improvável ajuste fiscal38:04 — Encerramento e agradecimentos

Invités : - Rodolphe Cart, journaliste et auteur de Mélenchon, le bruit et la fureur : Portrait d'un révolutionnaire aux éditions La Nouvelle Librairie  - Alexandre Malafaye, fondateur du think tank Synopia  - Jean-Michel Salvator, chroniqueur politique et communiquant Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Sonhos videntes, cartoes perdidos e pantufas

Drafting players based on their week 1 performances! A top 25 twinvestigation! Bold predictions for this weekend's marquee matchups! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Scottish Psalter | Richard Sibbes | Forgetting by Tim Schaufert | The Baker's Cart by Jean Michelin | Find more at www.ryanbush.org

In this latest episode of Wellness Junkies, we're diving into our newest product crushes - all tested, tried, and totally worth it. We're so excited to be back sharing the things we're genuinely loving lately. From viral TikTok finds to everyday staples that actually make a difference, this episode is all about the products helping us feel (and look) our best right now.We've been testing everything we talk about for at least three months, so these aren't just first impressions - they're real results from products that earned a spot in our routines. Expect honest reviews, fun discoveries, and a few surprises along the way.If you're in the mood for a little inspiration (and maybe a few new favorites), grab your matcha and tune in, because we did the testing so you don't have to. We hope you love this Product Junkies episode as much as we loved recording it - and maybe find a new favorite (or two) to add to cart.Brands/Mentions + Shop this episode: Shop here ⁠⁠⁠⁠⁠⁠For More on this Episode: Read the full show notes ⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠Join the community:Follow us ⁠⁠⁠⁠⁠@wellnessjunkiesofficial ⁠⁠⁠⁠⁠on InstagramSubscribe to our newsletterShop this episode + our faves on ⁠⁠⁠⁠⁠ShopMyShop⁠⁠⁠⁠⁠NEW! Follow us @wellnessjunkies on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠ and TikTokFollow Amy @amynicolle on TikTokVisit ⁠www.wellnessjunkiesofficial.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Shop our Amazon Store⁠⁠⁠⁠⁠Say hi: ⁠⁠⁠⁠⁠⁠⁠⁠⁠press@wellnessjunkiesofficial.com⁠⁠Please subscribe, rate, review + share to help us grow the community

We love to hear from our listeners. Send us a message.Episode 115 of Cell & Gene: The Podcast features Host Erin Harris' talk with Aliya Omer, Vice President and Global Head of Hematology and Cell Therapy at AstraZeneca. Omer shares valuable insights from her rich experience leading cell therapy development across multiple top companies. She highlights the critical importance of collaboration by breaking down silos across research, manufacturing, regulatory, and commercial teams to deliver innovative therapies efficiently. She also discusses AZ's diverse and ambitious cell therapy portfolio, encompassing autologous CAR-T, TCR-T, in vivo gene therapies, and regulatory T-cell therapies. She candidly addresses current challenges in manufacturing scalability, patient access, and healthcare system readiness and describes how AZ is prioritizing fast manufacturing platforms and ecosystem-wide partnerships to surmount these hurdles. Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Dr. Monty Pal and Dr. Pauline Funchain discuss the latest efforts to diagnose, prevent, and treat the series of immune-related adverse events that have emerged in the era of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am Monty Pal, a medical oncologist, professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles, California. Now, it is probably no surprise to this audience that immunotherapy has transformed the treatment landscape for multiple cancer types. It remains a pillar of modern oncology. Having said that, I think we have all been baffled by certain toxicities that we run into in the clinic. Today, I am delighted to be joined by Dr Pauline Funchain to discuss some of the checkpoint inhibitor toxicities that people struggle with most. And we will also touch on some side effects of immunotherapy beyond checkpoint inhibitors: CAR-T cells, bispecifics, so on and so forth. Dr Funchain is a dear friend, and she is an associate professor and associate director of cancer research training and education at the Stanford Cancer Institute. She is co-director of the Immunotherapy Toxicity Program and the Skin Cancer Genomics Program at Stanford, where she also serves as associate program director of hematology and oncology fellowship. Dr. Funchain is also the co-founder of ASPIRE, and we are going to talk about that a little bit today, the Alliance for the Support and Prevention of Immune-Related Events. FYI for listeners, if you are interested in our disclosures, they are available at the transcript of this episode. Pauline, thanks so much for joining us today. Dr. Pauline Funchain: Monty, thank you for this invitation. It is always great to talk. Dr. Monty Pal: So, for the audience, Pauline and I know each other from my days as a fellow at City of Hope. She was a resident at Harbor UCLA and a stellar resident at that. It has just been amazing to sort of see your career grow and blossom and to witness all the cool things that you are doing. ASPIRE, in particular, sort of caught my eye. So again, for listeners, this is the Alliance for the Support and Prevention of Immune-Related Events. Can you tell us a little bit briefly about the genesis of that, how that came about? Dr. Pauline Funchain: So, there was a bunch of us who were really struggling, I mean, all of us have struggled with these immune-related adverse events, these irAEs. You know, they are new disease states, and even though they look like autoimmune diseases, they tend to need a whole lot more steroid than autoimmune diseases do and they do not totally present in the same way. And in fact, you know, Triple-M, or Triple-M overlap syndrome, is a completely new irAE, a new immune state that we have never had before the advent of checkpoint inhibitor. And so a Triple-M, for those of you who are not as familiar, that is the constellation of myocarditis, myositis, and myasthenia gravis, something that never occurs as a natural autoimmune disease. So we were starting to realize that there were some major differences with these irAEs and autoimmune diseases. We could not treat them the right way. We really needed to learn more about them. And a bunch of us who had interest in this said, "Look, we really need to be all in one space to talk about what we are doing," because all of our treatments were our own little homegrown brews, and we needed to really get together and understand how to treat these things, how to diagnose them, and then learn more about them. So, Dr. Alexa Meara from Ohio State, Dr. Kerry Reynolds from Mass Gen, we put together this research consortium, brought together all of our irAE friends, got our best subspecialists together in a research consortium, which is now only about a year and a half old. And we made this research consortium, the Alliance for Support of Prevention of Immune-Related Events, and we reached out to ASCO, and ASCO was so kind to grant us a [Alliance for Support and Prevention of Immune-Related adverse Events (ASPIRE)] Community of Practice. So we met for the first time as a Community of Practice at the ASCO Annual Meeting just this past June and really got an ASCO community together to really think about how to again, diagnose, prevent, treat irAEs. Dr Monty Pal: This is interesting to me. The ASCO Community of Practice phenomenon is something that I was not super familiar with. Can you explain to our listenership what is the ASCO Community of Practice model? If you have particular interests, how do you sort of get one started? Dr Pauline Funchain: Yeah, so ASCO has an entire page on their Community of Practice. There are multiple Community of Practice groups or COPs. There are ones for Supportive Oncology and Survivorship. There is Women in Oncology. There is a group for International Medical Graduates. And there is about, I think 10 or 12 now that have a physical presence at ASCO but also a virtual presence on the ASCO Community of Practice site. So, if you were interested in any one of these, and you can see them on the ASCO Communities of Practice sites, you would ask to become a member. Once granted membership, then there is a whole webpage of postings and conversations that people can have. You can get email digests of conversations that happen on the website, and then you can anchor it with in-person participation at the Annual Meeting. Dr Monty Pal: That is awesome, and I can think of so many different foci within oncology that really sort of deserve a Community of Practice. This definitely being one of them. You know, it strikes me as being so interesting. I mean, the checkpoint inhibitors have been around for a while now. I think when you and I were in training, gosh, back then, these were just a little bit of a pipe dream, right? But having said that, I would probably say that more than half of my kidney cancer practice is either on checkpoint inhibitors, and the vast majority have been on one at some point in their past, right? With that in mind, you know, we have all treated a lot of patients with these drugs. Why is it that we still struggle to manage the toxicities? And just to take that one step further, what are some of the toxicities that, perhaps through ASPIRE or through your experience, people struggle with the most? Dr Pauline Funchain: So, I think we are still struggling with these because again, they are new disease states, right? This is what we all experienced with COVID, a brand-new virus and a brand-new syndrome. We now have 20-plus of these as irAEs. And what we have realized about them is the immune activation that happens with these is so much more than what we have seen with autoimmune diseases. So for instance, if you have a Crohn's or ulcerative colitis, you will top out at 40 to 60 milligrams of prednisone if a Crohn's flare or ulcerative colitis flare happens. But for our severe IR colitises, you know, it is at least 1 mg per kg, often goes up to 2 mg per kg. We, in some cases, have done 1 gram pulses if we are worried that somebody is going to perforate. So that was sort of like the first 5 years of treating irAE, and then now in the sort of second 5 years of treating irAE, we have realized that that is a lot of immunosuppression, and we might be able to get away with less with the newer biologics that are on board. So, we are struggling to try to get the data for some of these irAEs that we knew, we have known for a while, but to try to get newer treatments that may immunosuppress less so that you may still be able to retain that tumor response. And in fact, some of the preclinical studies suggest that some of these biologics may actually synergize with the immunotherapy and actually make the immunotherapy more effective from a tumor perspective and calm down the irAE as sort of the bystander effect. So we are still trying to optimize those. Getting up trials in the space has been very difficult. That is one of the reasons for the genesis of ASPIRE because we realized we needed to band together to have a bigger voice in that realm. Then there are other things that are brand new. So we talked about Triple-M. So Triple-M, again, with Triple-M or any myocarditis or myasthenia, I mean, there is about a 50% chance of death from irAE based on the literature. I think we are getting better at recognizing this, and so at Stanford we have some data to say that if you serially follow troponin, that maybe your outcomes are better. You can potentially lower the percentage of cases that are fatal because you can catch them early. I mean, this is all preliminary data, but again, these are all things that are evolving, and we do not all have the right answer. I mean, even the serial troponin thing, I think, is pretty controversial. And in fact, at one of our quarterly Zoom meetings that we are doing in ASPIRE in December is going to sort of flush out that controversy about serial troponin measuring and what is the best thing to use? Would you use something like abatacept or would you use ruxolitinib? Which one is better? I think there is a lot of controversy still about these things. Dr Monty Pal: You have really piqued my curiosity here because you think about the cons of treating irAEs, right? And I worry exactly about what you had mentioned, right, which is, "Gosh, what is going on with this tumor in terms of immunosuppression?" But you think about some of the newer agents, you mentioned ruxolitinib, I have heard of dasatinib, for instance, in this setting. Frankly speaking, a lot of these, as you point out, are really thought of as being also anticancer drugs. So you have really got me thinking about the potential synergy between perhaps suppressing an irAE and augmenting antitumor activity, which I think is very interesting. Am I on the right track with that? Dr Pauline Funchain: I think so, but you will find that a lot of people will not even go there because they are worried about how much immunosuppression you are going to cause. I am at heart a geneticist, but I think an immunologist will happily tell you that the immune system is very complex. There are multiple pathways, and these drugs do not all target the same immune pathways. So if we understand a little bit more about the pathways we are targeting and pick apart the pathways that are really, really tumor relevant and the other pathways that are not tumor relevant, you may be able to piece together a better marriage of tumor response and irAE control. Dr Monty Pal: Kind of on this topic, and again, leaning on your background in genetics, where are we in terms of predicting these irAEs? I mean, you would think the holy grail would be picking out a snip or something of this for it, right, that could potentially identify that patient who is going to get Triple-M or, you know, at the very least a significant high-grade irAE event. Are we anywhere closer to that in 2025? Dr Pauline Funchain: There have been data published. There have been some big GWAS studies. All of the effect sizes are pretty small. So there are some prediction algorithms, but none of them are clinically useful. And I think when you look at the odds ratios, they will increase risk by maybe 20%. I think one of the things that we found in a very small series and supported anecdotally is something as easy as family history of autoimmune disease is probably more predictive at this point than any of those types of markers. I think we will get there, but we are not anywhere near where we would like to be. Things like TMB also, actually, there is some good data about higher TMB, higher risk of irAE too. Dr Monty Pal: Interesting. I see all this data coming through, IL-8 polymorphisms, etc. And I just wondered if any of that was ready for prime time. But I mean, this is a good message for the practicing clinician. Sounds like we are not quite there yet. And I could probably keep you on for another entire podcast to talk about this topic, but let us see if we can at least skim the surface. I never thought I would see the day when BiTEs and CAR-Ts were entering into my kidney cancer practice, but in fact, it is really become central to a lot of our clinical trials in RCC these days. I would be lying if I did not say that I was not struggling with the toxicities and so forth associated with these drugs. Can you give us a quick primer, maybe just good resources that people can go to for managing toxicity with BiTEs and with CAR and with some of these novel therapeutic modalities that we are using in the oncology clinics? Dr Pauline Funchain: I know there is a recently published toxicity manual for BiTEs in hematologic malignancies, I think it was in Blood. CAR-T is covered in many irAE guidelines. So ASCO guidelines actually has a CAR-T [cell therapy guideline], and I would be remiss not to point out that actually ASCO has a, I am a little biased, but a wonderful guideline on irAE that is actually being updated as we speak. We are hoping for publication next year. I find the format of that, there are many guidelines out there, actually. There is ASCO, SITC, ESMO has a guideline for irAE, but I find the formatting of the ASCO guideline to be much easier to flip through during clinic, just because of the visual format of the tables. But that is going to be updated next year. And with CAR-T, there is now multiple publications also in terms of guidelines. But what I will say about bispecifics and CAR-T, so they have very similar toxicities in terms of the cytokine release and also with the ICANS, so the neurotoxicity. But what we have been finding that is really interesting with BiTEs and CAR-T, and actually even with TIL, cytokine release is very similar to some of the IL-2 toxicities but not identical that we see with TIL treatment. But now we are starting to see overlap. So patients who have been treated with immunotherapy and then go on to get a bispecific or then go on to get TIL, so I have seen some colitises that have occurred after the fact. Some of the newer CAR-Ts without checkpoint have been causing some really interesting, probably not in a good way, but interesting biologically, colitises that are really refractory. So we are starting to see some overlap, and again, I think this field is just evolving constantly. Dr Monty Pal: Yeah, no, I almost think I need to go back to that fellowship that you and I did together 20 years ago and, you know, and see if I could repeat some coursework on CAR-T management.  You know, Pauline, I could probably keep you on the horn for hours, but this has just been terrific. Thank you so much for sharing all of your insights with us today on the ASCO Daily News Podcast. Dr Pauline Funchain: Thank you for the invitation. It was wonderful to talk about this, and it was wonderful to catch up a little bit, Monty. Dr Monty Pal: Same here, same here. And thanks to our listeners too. If you value the insights you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:      Dr. Monty Pal    @montypal   Dr. Pauline Funchain @FunchainMD Follow ASCO on social media:       @ASCO on Twitter      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn     Disclosures: Dr. Monty Pal:     Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview    Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Pauline Funchain: Consulting or Advisory Role: Merck, Replimune, Sanofi/Regeneron, Immunocore, Tempus Research Funding (Inst.): Pfizer, Bristol-Myers Squibb, IDEAYA Biosciences, Linnaeus Therapeutics Travel, Accommodations, Expenses: Merck

In this value-packed episode, e-commerce expert Matthew Stafford shares how understanding and responding to real customer data powers dramatic business growth and website conversion lifts. Matthew describes his journey from ad specialist to conversion optimization guru—driven by necessity, continuous learning, and a genuine passion for data-driven problem-solving. Together with Jeff Mains, they dive into practical strategies for removing friction from your site, the science of micro-commitments, actionable post-purchase surveys, and how to build websites that truly speak to your ideal customers. Whether you're in SaaS or e-commerce, this episode delivers actionable steps to boost conversions, collect meaningful insights, and lead your team to sustained success.Key TakeawaysThe Power of Website Data (00:00:00)Deeply understanding what users actually do on your site beats guessing or bias. Data is “agnostic” and reflects real user behavior.Solve the Right Problems with Data-Driven Insights (00:01:05)Tracking analytics turned Matthew's declining sales around from loss to profitability.Post-Purchase Surveys Drive Revenue (00:05:01)Implement a simple post-purchase question: “What almost stopped you from buying?” The answers lead to multi-million dollar wins.Micro-Commitments & Button Text (00:13:11)“Buy now” creates friction. Instead, use action-specific steps like “Add to Cart” or “Learn More” to lead customers smoothly to purchase.Focus on Simplicity & Clarity (00:10:43)Clarity always trumps persuasion. Present the next necessary action clearly and reduce choices to avoid customer confusion.Start Optimization at the Checkout, Work Backwards (00:27:51)Always optimize conversion pages (checkout, cart, product page) before iterating on the homepage or filters.Tweetable Quotes"The data is agnostic. It doesn't care what you're thinking—it just tells you exactly what they're doing." —Matthew Stafford"Clarity trumps persuasion. Make your site so simple that Homer Simpson would understand it." —Matthew Stafford"If you describe the problem better than your customer can, they'll assume you have the solution." —Matthew Stafford"Stop treating customers like transactions. Treat them like your mom—build real relationships." —Matthew Stafford"People don't want to click on a button if they don't know where it's taking them. Make every step clear." —Matthew Stafford"You don't have a brand until you can stop running ads and survive. Until then, you just have a good funnel." —Matthew StaffordSaaS Leadership LessonsBe Willing to Learn Before DelegatingMatthew learned analytics himself before hiring, allowing him to hire better and direct vision with confidence.Let Data Be Your GuideRemove ego and personal preference; let unbiased customer data inform and drive your decisions.Prioritize Problems with Greatest Revenue ImpactStart optimization where money changes hands, not where you “feel” the problem is.Don't Redesign for VanityAvoid unnecessary redesigns driven by boredom or internal desire for novelty; new visitors see your site for the first time.Embrace Customer ConversationsReal feedback, surveys, and live chats are goldmines for improvement and repeat sales.Iterate with Focused ExperimentsTest, don't guess: collect feedback, run tests on focused elements, and double down on what specifically works.Guest...

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Listen to the podcast here

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Download the transcript here

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-cell lymphoma in a study with 245 patients. Findings show a tentative way forward in treatment for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Featured Article:Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Revolutionizing Retail: Drew Ann Long's Caroline's Cart Journey In this episode of 'Why Not Me', hosted by Tony Mantor from Nashville, Tennessee Drew Ann Long shares her inspiring story of creating Caroline's Cart—a revolutionary shopping cart designed for individuals with special needs. Drew Ann, motivated by her daughter Caroline's severe disabilities, overcame numerous challenges, financial hurdles, and industry skepticism to bring her vision to life. Despite initial rejections from manufacturers, Drew's relentless pursuit led to global recognition and adoption of Caroline's Cart, transforming accessibility in retail. She also discusses the formation of Caroline's Cause, a nonprofit providing scholarships to families with special needs children. Drew's journey highlights the impact of empathy-driven innovation and the importance of taking bold risks to make a difference. Meet Drew Ann Long: Founder of Caroline's Cart The Birth of Caroline's Cart Challenges and Breakthroughs The First Prototype and Social Media Explosion Manufacturing Struggles and Success Nationwide and International Expansion Caroline's Cause: Giving Back Future Plans and Continued Growth Closing Thoughts and Contact Information Music written By T. Wild Mantor Music BMI The content on Why Not Me: Embracing Autism amd Mental Health Worldwide, including discussions on mental health, autism, and related topics, is provided for informational and entertainment purposes only. The views and opinions expressed by guests are their own and do not reflect those of the podcast, its hosts, or affiliates.Why Not Me is not a medical or mental health professional and does not endorse or verify the accuracy, efficacy, safety of any treatments, programs, or advice discussed.Listeners should consult qualified healthcare professionals, such as licensed therapists, psychologists, or physicians, before making decisions about mental health or autism- related care.Reliance on this podcast's contents is at the listener's own risk. Why Not Me is not liable for any outcomes, financial or otherwise, resulting from actions taken based on the information provided. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Sánchez comparece en el Senado y califica la comisión de circo, evadiendo preguntas clave con un recurrente "no me consta". Se le acusa de encenagamiento político y de no ofrecer explicaciones convincentes sobre su presunta implicación en casos de corrupción. En Pamplona, cuatro argelinos son detenidos por agresión sexual y robo. El embajador de Japón en España, Takahiro Nakamae, finaliza su misión, siendo reconocido por su dedicación al país. Se analiza que Sánchez sale vivo de la comparecencia, pero acorralado y sin ofrecer claridad. La inflación se dispara, afectando la luz, viajes y billetes de tren. En deportes, se juega la Copa del Rey y la Liga. A nivel internacional, Trump anuncia la reanudación de pruebas nucleares y se observa un deshielo comercial entre EE.UU. y China. El Hospital de La Paz presenta una terapia pionera con células CAR-T para la leucemia infantil, logrando resultados esperanzadores. COPE informa sobre la agenda de Madrid, incluyendo un dispositivo de ...

-SNAP benefits are running out due to the Schumer Shutdown, and Rob suggests giving to your local food bank — or preparing to ankle-tackle grocery thieves like a patriotic linebacker. -Between rants about the bourgeoisie, fentanyl, and golf carts, Rob declares the Democrat Party dead, buried, and possibly returning as a zombie by the midterms. Today's podcast is sponsored by : BEAM DREAM POWDER : Improve your health by improving your sleep! Get 40% off by using code NEWSMAX at http://shopbeam.com/NewsmaxGET FRESH OLIVE OIL : Try real farm fresh olive oils for FREE plus $1 dollar shipping at http://GetFreshRobCarson.comBIRCH GOLD - Protect and grow your retirement savings with gold. Text ROB to 98 98 98 for your FREE information kit! To call in and speak with Rob Carson live on the show, dial 1-800-922-6680 between the hours of 12 Noon and 3:00 pm Eastern Time Monday through Friday…E-mail Rob Carson at : RobCarsonShow@gmail.com Musical parodies provided by Jim Gossett (www.patreon.com/JimGossettComedy) Listen to Newsmax LIVE and see our entire podcast lineup at http://Newsmax.com/Listen Make the switch to NEWSMAX today! Get your 15 day free trial of NEWSMAX+ at http://NewsmaxPlus.com Looking for NEWSMAX caps, tees, mugs & more? Check out the Newsmax merchandise shop at : http://nws.mx/shop Follow NEWSMAX on Social Media:  -Facebook: http://nws.mx/FB  -X/Twitter: http://nws.mx/twitter -Instagram: http://nws.mx/IG -YouTube: https://youtube.com/NewsmaxTV -Rumble: https://rumble.com/c/NewsmaxTV -TRUTH Social: https://truthsocial.com/@NEWSMAX -GETTR: https://gettr.com/user/newsmax -Threads: http://threads.net/@NEWSMAX  -Telegram: http://t.me/newsmax  -BlueSky: https://bsky.app/profile/newsmax.com -Parler: http://app.parler.com/newsmax Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we dive into how to run the best promotions for Black Friday and Cyber Monday (BFCM). Nathan Ho, Product Manager of EasyGift, shares his experience and advice on structuring promotions, using tiered spending to increase average order value, and the power of free gifts. He also discusses different marketing strategies like scheduled rules and audience targeting to maximize sales during the busiest shopping days.Topics discussed in this episode:  How to start preparing for Black Friday as early as possible.What tiered minimum spend promotions are and why they work.Why a free gift is a strong trigger to encourage customers to buy more.How to use gifts as product samples to introduce new items.What scheduled rules are for setting time-specific deals.How to simplify promotions to avoid confusing your customers.What the classic promotion triggers are: cart value, products, and collections.How to use magic links to target new customers from ads.Why testing promotions before launch is critical to avoid conflicts.What optimizing shipping can do to stand out from competitors.Links & Resources Website: https://www.506.io/easygiftShopify App Store: https://apps.shopify.com/gifter-cart-auto-includeLinkedIn: https://www.linkedin.com/company/506-io/X/Twitter: https://twitter.com/506_appsGet access to more free resources by visiting the show notes at https://tinyurl.com/ab8jb8p3______________________________________________________ LOVE THE SHOW? HERE ARE THE NEXT STEPS! Follow the podcast to get every bonus episode. Tap follow now and don't miss out! Rate & Review: Help others discover the show by rating the show on Apple Podcasts at https://tinyurl.com/ecb-apple-podcasts Join our Free Newsletter: https://newsletter.ecommercecoffeebreak.com/ Support The Show On Patreon: https://www.patreon.com/EcommerceCoffeeBreak Partner with us: https://ecommercecoffeebreak.com/partner-with-us/

This week Emily gets artsy over the man behind CARTdepartment.         SHOW NOTES: Larry Warsh interview Jay Z, Kanye West Otis music video Lots of CART car pics  @cartdept Recorded, edited & mixed by Emdognightmare & Queen of the Vans Production & research Queen of the Vans & Emdognightmare Find us: Car Krush Stay updated w/ our newsletter Hugs, thank you & high fives to Greg Meleney for the killer tunez!

This month, the gals are joined by Trevin from Live, Laugh, Larceny Podcast to discuss a wiener catastrophe, poop spray damage, Sierra's stains, litter at the country club, a food critic for the people, and the most accident-prone pastor you've ever heard of. Tune in for October's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

Radio Foot à 16h10-21h10 T.U. à la Une ce lundi : - Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! ; - Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? Le 262è Clásico, premier de la saison, bascule du côté du Real Madrid ! Un an et demi de disette pour les Blancos, une première référence pour les Merengue et Xabi Alonso. Sans Raphinha ni Lewandowski, l'homme en forme des Blaugranas, Fermin Lopez, a permis aux Catalans de revenir. Mbappé décisif, même si le Kyks a vu Szczesny stopper sa tentative de penalty. Le but refusé de la 12è minute. Une célébration de courte durée. La frustration du hors-jeu semi-automatique ? Autre frustration, celle de Vinicius Jr, remplacé par Rodrygo à 20 minutes de la fin. - Lamine Yamal bien muselé par Alvaro Carreras, une fin de match sous tension. Le Real en profite pour se détacher, compte 5 points d'avance sur son rival catalan.   Ligue 1, Paris s'impose à Brest grâce notamment à Achraf Hakimi, et reprend les commandes de la L1. Un retour à la normale ? L'OM s'était installé dans le fauteuil de leader, mais encaisse une 2è défaite d'affilée. Après la déconvenue du Sporting en C1, les Phocéens battus à Lens. Ils n'auront gardé l'avantage que 7 minutes. Nouvelle soirée de cauchemar pour Benjamin Pavard, après celle de Lisbonne mercredi dernier. On n'arrête plus les Sang et Or de Pierre Sage, qui s'emparent de la 2è place, la 10è journée se joue mercredi. Pour débattre avec Hugo Moissonnier, Manu Terradillos, Hervé Penot et Dominique Sévérac. Technique/réalisation : Laurent Salerno - Pierre Guérin.

On today episode, Andy & DJ discuss ICE rolling Portland protester away on flatbed cart as Trump says city is burning to the ground, a bloody Mark Sanchez seen stumbling down Indianapolis sidewalk after being stabbed in fight with grease truck driver, and a brand new segment of AI or Nah.